Баклосан: Литература

Комментарии Баклосан. (Возможности фармакологической терапии в неврологии)
  1. Парфенов В.А. Ведение больных со спастичностью. Русский Медицинский Журнал, Том 12 №10, 2004.
  2. Гусев Е.И., Гехт А.Б. Спастичность. Русский Медицинский Журнал, Том 7 №12, 1999.
  3. Чуканова Е.И. Миорелаксация – ведущее звено в терапии болезненного мышечного спазма. Медицинская газета «Здоровье Украины», № 91, 2004.
  4. Бурчинский С.Г. Принципы и средства фармакологической коррекции болевых спастических синдромов в неврологии. Институт геронтологии АМН Украины, Киев. Клинический обзор.
  5. Белова А.Н. Спастический паралич. Нейрореабилитация: Руководство для врачей. Глава 4. Принципы восстановительного лечения при основных неврологических синдромах. Москва, 2000.
  6. Reis G.M., Duarte I.D. Baclofen, an agonist at peripheral GABAB receptors, induces antinociception via activation of TEA-sensitive potassium channels. Br J Pharmacol. 2006 Nov;149(6):733-9. Epub 2006 Oct 3.
  7. Potes CS, Neto FL, Castro-Lopes JM. Administration of baclofen, a gamma-aminobutyric acid type B agonist in the thalamic ventrobasal complex, attenuates allodynia in monoarthritic rats subjected to the ankle-bend test. J Neurosci Res. 2006 Feb 15;83(3):515-23.
  8. Lind G, Schechtmann G, Winter J, Meyerson BA, Linderoth B. Baclofen-enhanced spinal cord stimulation and intrathecal baclofen alone for neuropathic pain: Long-term outcome of a pilot study. Eur J Pain. 2007 Apr 30.
  9. He L, Wu B, Zhou M. Non-antiepileptic drugs for trigeminal neuralgia. Evid Based Dent. 2006;7(4):107.
  10. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Annals of Neurology 1984;15(3):240-4.
  11. Parekh S, Shah K, Kotdawalla H, Gandhi I. Baclofen in carbamazepine resistant trigeminal neuralgia - A double blind clinical trial. Cephalalgia 1989;9(Suppl 10):392-3.
  12. Fromm GH, Terrence CF. Comparison of L-baclofen and racemic baclofen in trigeminal neuralgia. Neurology 1987;37(11):1725-8.
  13. Fromm GH, Aumentado D, Terrence CF. A clinical and experimental investigation of the effects of tizanidine in trigeminal neuralgia. Pain 1993;53(3):265-71.
  14. Vilming ST, Lyberg T, Lataste X. Tizanidine in the management of trigeminal neuralgia. Cephalalgia 1986;6(3):181-2.
  15. Lindstrom P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 1987;28(1):45-50.
  16. Kondziolka D, Lemley T, Kestle JR, Lunsford LD, Fromm GH, Jannetta PJ. The effect of single-application topical ophthalmic anesthesia in patients with trigeminal neuralgia. A randomized double-blind placebo-controlled trial. Journal of Neurosurgery 1994;80(6):993-7.
  17. Carasso RL, Yehuda S, Streifler M. Clomipramine and amitriptyline in the treatment of severe pain. The International Journal of Neuroscience 1979;9(3):191-4.
  18. DT Shakespeare, M Boggild, C Young. Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews 2003, Issue 4.
  19. Basmajian JV, Yucel V. Effects of GABA-derivative (BA-34647) on spasticity. Preliminary report of a double-blind cross-over study & rehabilitation. American Journal of Physical Medicine 1974;53(5):223-8.
  20. Basmajian JV. [Lioresal (baclofen) treatment of spasticity in multiple sclerosis]. American Journal of Physical Medicine 1975;54(4):175-7
  21. Basmajian JV, Shankardass K, Russell D. Ketazolam treatment for spasticity: double-blind study of a new drug. Archives of Physical Medicine & Rehabilitation 1984;65(11):698-701
  22. Basmajian JV, Shankardass K, Russell D. Ketazolam once daily for spasticity: double-blind cross-over study. Archives of Physical Medicine and Rehabilitation 1986;67(8):556-7.
  23. Bass B, Weinshenker B, Rice GP, Neseworthy JH, Cameron MG, Hader W, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Canadian Journal of Neurological Sciences 1988;15(1):15-9.
  24. Chrzanowski, C. A new muscle relaxant, DS 103-282, versus baclofen in the treatment of chronic spasticity. 8th International Congress of Physical Medicine & Rehabilitation. Sweden: Print Minab, 1980:45.
    Chrzanowski K. A comparative trial of tizanidine and baclofen in the treatment of spasticity due to multiple sclerosis (study no. 26). Unpublished Sandoz Research Report 1981.
  25. Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Current Medical Research & Opinion 1988;10(10):699-708.
  26. Feldman RG, Kelly-Hayes M, Conomy JP, Foley JM. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology 1978;28(11):1094-8.
  27. Brar Sp, Smith MB, Nelson LM, Franklin GM, Cobble ND. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Archives of Physical Medicine & Rehabilitation 1991;72(3):186-9.
  28. Smolenski C, Muff S, Smolenski-Kautz S. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Current Medical Research & Opinion 1981;7(6):374-83.
  29. Stien R, Nordal HJ, Oftedal SI, Slettebo M. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurologica Scandinavica 1987;75(3):190-4.
  30. Wuthrich, R. A comparative trial of tizanidine and baclofen in the treatment of spasticity due to multiple sclerosis (study No 31). Unpublished Sandoz Research Report 1981.
  31. Pellkofer M, Paulig M. Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities. Medizinische Klinik 1989;84(1):5-8.
  32. Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Archives of Neurology 1977;34(7):422-8
  33. M Taricco, R Adone, C Pagliacci, E Telaro. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database of Systematic Reviews 2000, Issue 2.
  34. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS. Intrathecal baclofen for severe spinal spasticity. New England Journal of Medicine 1989;320(23):1517-21.
  35. Hugenholts H, Nelson RF, Dehoux E, Bickerton R. Intrathecal baclofen for intractable spinal spasticity-a double blind crossover study in eight patients. Canadian Journal of Neurological Sciences 1992;19:188-95.
  36. Burke D, Gillies JD, Lance JW. An objective assessment of a gamma aminobutyric acid derivative in the control of spasticity. Proceeedings of the Australian Association of Neurology 1971;8:131-4.
    Jones RF, Burke D, Marosszeky JE, Gillies JD. A new agent for the control of spasticity. Journal of Neurology, Neurosurgery and Psychiatry 1970;33(4):464-8.
  37. Guglielmino A, Sorbello M, Fazzio S, Zingale SF, Bucolo GE, Pittala G, Castiglione A, Patti F, Mangiameli S. Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience. Minerva Anestesiol. 2006 Oct;72(10):807-20
  38. Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, Ling W. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006 Dec 1;85(3):177-84. Epub 2006 Jun 5.
  39. Albright AL, Ferson SS. Intrathecal baclofen therapy in children. Neurosurg Focus. 2006 Aug 15;21(2):e3.
  40. Taira T, Ochiai T, Goto S, Hori T. Fifteen year experience of intrathecal baclofen treatment in Japan. Acta Neurochir Suppl. 2006;99:61-3.
  41. Richard I, Menei P. Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders. Acta Neurochir Suppl. 2007;97(Pt 1):213-8.
  42. Flannery BA, Garbutt JC, Cody MW, Renn W, Grace K, Osborne M, Crosby K, Morreale M, Trivette A. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res. 2004 Oct;28(10):1517-23.
  43. Lechin F, van der Dijs B, Lechin ME, Amat J, Lechin AE, Cabrera A, et al. Pimozide therapy for trigeminal neuralgia. Archives of Neurology 1989;46(9):960-3.
  44. Воробьева О.В., Козлова И.М. Возможности баклофена в комплексной анальгезии пациентов с острой неспецифической болью в спине. Consilium-medicum.Том 08/N 8/2006 .
  45. Shoptaw S, Yang X, Rotheram-Fuller EJ, Hsieh YC, Kintaudi PC, Chauvastra VC, Lind W. Randomized placebo-controlled trial of baclofen for cocsine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 2003 Dec;64(12):1440-8.
  46. Shelenberger MK, Groves L, Novack GD. A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. Drug Metab Dispos. 1999 Feb;27(2):201-4.
  47. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. Copyright 2004.
Баклосан. (Возможности фармакологической терапии в неврологии)
1 декабря 2009 г.
Комментарии (видны только специалистам, верифицированным редакцией МЕДИ РУ)
Если Вы медицинский специалист, войдите или зарегистрируйтесь

МЕДИ РУ в: МЕДИ РУ на YouTube МЕДИ РУ в Twitter МЕДИ РУ на FaceBook МЕДИ РУ вКонтакте Яндекс.Метрика